EP3294285

AVENTIS PHARMA
Application Number
EP16721844A
Filing Date
May 12, 2016
Status
Revoked
Dec 16, 2022
Grant Date
Dec 18, 2019
External Links
Slate, Register, Google Patents
Similar Patents facing opposition

Biblio Summary

The patent EP3294285B1 was granted on Dec 18, 2019 by Aventis Pharma . The latest application status of the patent is - Revoked.

AI Generated Summary New

Patent Oppositions filed by Competitors

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATESep 18, 2020ADMISSIBLE
ZENTIVASep 18, 2020ADMISSIBLE
STADA ARZNEIMITTELSep 17, 2020ADMISSIBLE
GENERICS UKSep 16, 2020ADMISSIBLE
DR REDDYS LABORATORIES BETAPHARM ARZNEIMITTELAug 26, 2020ADMISSIBLE
FRESENIUS KABI DEUTSCHLANDJul 9, 2020ADMISSIBLE
HEXALJul 1, 2020ADMISSIBLE
TEVA PHARMACEUTICAL INDUSTRIESJun 9, 2020WITHDRAWN
ACCORD HEALTHCAREJun 3, 2020ADMISSIBLE

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents